2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
22
Neoplasms
15
Pulmonary Embolism
10
Venous Thrombosis
9
Thrombosis
6
Multiple Myeloma
4
Upper Extremity Deep Vein Thrombosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Interventions
Pancreaticojejunostomy
4
Endoscopic Mucosal Resection
3
Octreotide
2
obeticholic acid
1
fludarabine
1
apixaban
1
aldesleukin
1
X-Rays
1
Ursodeoxycholic Acid
1
Tranexamic Acid
1
Tissue Adhesives
1
Tea
1
Surgical Procedures, Operative
1
Stents
1
Specimen Handling
1
Sodium Chloride
1
Rivaroxaban
1
Radiotherapy
1
Radiosurgery
1
Phantoms, Imaging
1
Pantoprazole
1
Nutritional Status
1
Nutrition Therapy
1
Irinotecan
1
Iopamidol
1
Hydromorphone
1
Hydrocortisone
1
High-Energy Shock Waves
1
Epinephrine
1
Enteral Nutrition
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Duodenal Neoplasms
×
apixaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled